# A Case Report on Pantoprazole Induced VIT.B<sub>12</sub> Deficiency

Ranakishore Pelluri<sup>\*</sup>, Shaik Shafiya Begum, Nallajerla Sowmya, Medarametla Jyothsna, S. Prathyusha, Yedluri Divya, Tadipudi Poornachand, Thirupathi Vivek Reddy, Kakumanu Jhansirani, B. Umamounika, Nadendla Ramarao

Department of Pharmacy Practice, Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur-A.P, INDIA.

#### ABSTRACT

A 40 yr old male patient suffering with GERD was initially prescribed with Pantoprazole 40 mg OD for 15 days. After the treatment, suddenly the patient started feeling uncharacterized dizziness and fatigue. The patient consulted his physician who is a gastroenterologist. After a thorough examination the physician asked the patient for blood tests which revealed that the Hb is normal but the amount of Vit.B<sub>12</sub> present in the blood is less than the normal. It was confirmed that, after the use of Pantoprazole, Vit.B<sub>12</sub> blood levels have decreased which lead to the symptoms. This case report summarizes that on long term use of pantoprazole should be supported by supplemental therapy with Vit.B<sub>12</sub> Background: Proton pump inhibitors (PPI) are now one of the most widely used classes of drugs. PPIs have proven to have a very favourable safety profile and it is unusual for a patient to stop these drugs because of side effects. However, increasing numbers of patients are chronically taking PPIs for gastroesophageal reflux disease and a number of other common persistent conditions, therefore the long-term potential adverse effects are receiving increasing attention. One area that is receiving much attention and generally has been poorly studied is the long-term effects of chronic acid suppression on the absorption of vitamins and nutrients.

Key words: Pantoprazole, Gastroesophagal reflux disease, Gastric ulcer, Vitamin B<sub>1,2</sub> Deficiency, Dizziness.

#### **CASE PRESENTATION**

An ADR report concerning a patient who developed vitamin  $B_{12}$  deficiency while being treated with pantoprazole. The patient, who had been treated with pantoprazole 40 mg for gastroesophageal reflux disease with gastric ulcer for 15 days. After this, the patient consulted his physician about uncharacteristic symptoms including periodic dizziness. Blood examinations revealed Vitamin B<sub>12</sub> deficiency. The patient was examined, and no other causes were found that could explain the inability to absorb Vitamin B<sub>12</sub>. After Pantoprazole was discontinued, serum  $B_{12}$  levels normalized.

### TREATMENT

Withdrawal of the drug has relieved the patient from the unexplained periodic dizziness., and vitamin supplements was provided to that patient.

#### **Outcome And Followup**

The patient remained free of symptoms after he was given syrup Vit. $B_{12}$ .

#### DISCUSSION

The proton pumps inhibitors (PPIs) as a Lam, Guntur-A.P, INDIA. class is remarkably safe and effective for Phone no: 9032694102 persons with peptic ulcer disorders.<sup>1</sup> Anemia has frequently been reported as the only manifestation or the most frequent extraintestinal symptom of celiac disease. Anemia due to isolated cobalamin deficiency is a frequent finding in the elderly, and its etiology goes beyond the classical pernicious anemia concept.<sup>2</sup> Deficiency of vitamin B<sub>12</sub> is also common in CD and frequently results

Submitted date : 13/01/2015 Accepted date : 28/01/2015

DOI: 10.5530/ijopp.9.1.13

#### Address for correspondence: Ranakishore Pelluri,

Department of Pharmacy Practice, Chalapathi Institute of Pharmaceutical Sciences, E-mail: ranampharm@gmail.



in anemia.<sup>3</sup> PPIs reduce gastric acidity, which is necessary to activate pepsinogen to pepsin to release vitamin  $B_{12}$ from B<sub>12</sub>-containing foods. PPIs used short-term may minimally reduce the absorption of protein-bound  $B_{12}$ in food.<sup>4 5 6</sup> Long-term use of PPIs does not lead to vitamin B<sub>12</sub> deficiencies, except possibly in the elderly or in persons with ZES (Zollinger's Ellison syndrome) who are on high doses of PPI for prolonged periods of time.7,8 PPIs have been associated with an increased risk of vitamin and mineral deficiencies impacting vitamin B<sub>12</sub>, vitamin C, calcium, iron and magnesium metabolism. No current evidence recommends routine screening or supplementation for these potential vitamin and mineral deficiencies in patients on either short-or long-term PPI therapy. Reducing inappropriate prescribing of PPIs can minimize the potential risk of vitamin and mineral deficiencies.9 Vitamin B<sub>12</sub> (cobalamin) is an essential water soluble nutrient acquired from animalderived food sources including meat, fish, shellfish, poultry, eggs and dairy products. Lacto-ovo vegetarians are generally not considered to be at risk for deficiency, while true vegans may risk deficiency unless they consume supplements or vitamin B<sub>12</sub> fortified foods including cereals and soy-based products. Since, the common human diet contains substantially more vitamin  $B_{12}$ than is required, a large functional reserve with respect to vitamin B<sub>12</sub> absorption is assumed.<sup>10</sup> Evidence-based guidelines supporting proton pump inhibitor (PPI) use as the superior option for antisecretory therapy for treatment of non erosive gastro esophageal reflux disease (GERD).11

The overall benefits of therapy and improvement in quality of life significantly outweigh potential risks in almost all patients. Risk stratification of elderly, frail, malnourished, dialyzed and chronically hospitalized patients should direct clinicians to measure benefits of therapy against risks.

### **Learning Points**

# Doctors, Pharmacists & Nursing staff should be aware of the following:

 Pantoprazole, as all acid-blocking medicines, may reduce the absorption of Cyanocobalamin due to hypo- or Achlorhydria.  This should be considered for patients with reduced Cyanocobalamin stores (low plasma cobalamins) or other risk factors for reduced Cyanocobalamin absorption on long-term therapy or if respective clinical symptoms are observed (symptoms of anemia).

## ACKNOWLEDGEMENT

The authors convey their sincere thanks to the patient and also to the physician who have co-operated with us throughout the work

## **CONFLICT OF INTEREST**

The Author declare no conflict of interest.

### **ABBREVIATIONS USED**

GERD:	Gastro esophageal reflux disorder
PPI:	Proton Pump Inhibitor
ADR:	Adverse drug reaction
ZES:	Zollinger's Ellison syndrome

# REFERENCES

- Thomson AB, Sauve MD, Kassam N. Safety of the long term use of proton pump inhibitors. World J Gastroenterol. 2010;16(19):16:2323-30.
- Fernando FB, Helena M, Montserrat F. A short review on anemia and malabsorption. World J Gastroenterol. 2009;15(37):4644-52.
- Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood. 2007;109:412-21.
- Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B<sub>12</sub>). Ann Intern Med. 1994;120:211-15.
- Saltzman JR, Kemp JA, Golner BB, Pedrosa MC, Dallal GE, Russell RM. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on proteinbound vitamin B<sub>12</sub> absorption. J Am Coll Nutr. 1994;13:584-91.
- Schenk BE, Festen HP, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther. 1996;10:541-45.
- Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(Suppl 2):S2-S4.
- McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):S5-S9.
- Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Adv Drug Saf. 2013;4:125-133.
- Howden C. Vitamin B<sub>12</sub> levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30:29-33.
- DeVault K, Castell D. Updated guidelines for the diagnosis and treatment of gastro esophageal reflux disease. Am J Gastroenterol. 2005;100:190-200.